Clinical and pathologic characteristics of mCRPC were largely similar between younger and older patients. Overall survival was not significantly different between younger and older patients with mCRPC ...
Preliminary results of a combined home and rural outpatient clinic-based infusion program through the Veterans Health Administration: A single-center experience. This is an ASCO Meeting Abstract from ...
After failure of HT, in addition to secondary hormonal manipulation (antiandrogens, ketoconazole with steroids and estrogens), these are currently the drugs approved by the US FDA for initial therapy ...
Implementing comprehensive population-wide genomic testing in metastatic prostate cancer (mPCa): A real-world Canadian cohort study. This is an ASCO Meeting Abstract from the 2026 ASCO Genitourinary ...
In patients with BRCA2-mutated mCSPC, treatment with Akeega significantly reduced the risk of radiographic progression or death by 54%. The Food and Drug Administration (FDA) has approved Akeega ® ...
Darolutamide (Nubeqa) is granted FDA approval for metastatic castration-sensitive prostate cancer, enhancing survival and quality of life for patients. The FDA has approved darolutamide (Nubeqa; Bayer ...
Nubeqa (darolutamide) received FDA approval for metastatic castration-sensitive prostate cancer, showing significant improvement in radiographic progression-free survival. The ARANOTE trial involved ...
In preclinical prostate cancer models, HLD-0915 treatment resulted in tumor shrinkage and declines in prostate-specific antigen. The Food and Drug Administration (FDA) has granted Fast Track ...
Immunotherapies use the power of your immune system to fight your cancer. Vaccines are one form of immunotherapy. Sipuleucel-T is a vaccine used for advanced, metastatic prostate cancer if: It no ...
Cancer patients in Central Pennsylvania now have greater access to an advanced prostate cancer treatment with the launch of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results